OBM Geriatrics

(ISSN 2638-1311)

OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 6 days from acceptance to publication (median values for papers published in this journal in the first half of 2019, 1-2 days of FREE language polishing time is also included in this period).

Free Publication in 2019
Current Issue: 2019  Archive: 2018 2017

Special Issue

Aging and Alzheimer’s Disease

Submission Deadline: February 15, 2020 (Open)                Submit Now

Guest Editor

Md. Golam Sharoar
Department of Neurosciences, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030, USA
E-mail: sharoar@uchc.edu
Research Interests: Neurodegenerative diseases; Alzheimer’s disease; neurodegeneration

About This Topic

Alzheimer's disease (AD) is the most common form of dementia, accounts for 60-80 % of dementia cases. Currently, ~ 50 million people are believed to be living with AD and other dementia, which are estimated to be reached at 150 million by 2050. Aging is the most predominant factors for AD onset. The onset prevalence increases from 16% at 65-74 years age group to 81% among older people of 75 years and over. While the initial symptoms of AD vary person to person, the cognitive impairment (memory decline) is typically one of the first noticeable AD clinical symptom. As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self-care, and behavioral issues. The cost of dementia care worldwide has estimated around US$ 1 trillion per year. This special issue will seek to address a broad area of topics related to the causes, care and management of AD, and discuss interventions/solutions to prevent AD among aging population.​

Newsletter

TOP